The latest breakthrough in cancer treatment has been made… Introducing a new type of therapy that targets an oncometabolite has proved to make a real impact as it has produced dramatic results in patients with advanced leukemia, although this is only in the early stages of clinical trials it is clear that this new drug is a glimmer of hope to all. Roughly 15% of patients with acute myeloid luekemia have a mutated form of a gene called IDH2, this gene in someone of full health would usually produce a protein in which plays an extremely important role in cell metabolism. However when the gene is mutated there is an increase in the production of 2- hydroxyglutrate, this prevents immature white blood cells from forming into healthy cells with the ability to fight infecting cells. The cells then accumulate & crowd the normal cells, leading to the eventual development of acute leukemia. The AG-221 drug blocks the mutated IDH2 protein, allowing immature white blood cells to develop healthily. Unlike traditional forms of cancer therapy there are very little side effects to the drug as it targets the disease much more precisely. Instead of inhibiting a mutation, leading to cancer cell growth, it targets a gene in which is able to be manipulated, transforming cells making them healthy once again. 45 patients took part in the trial, completing one cycle of therapy; they were then evaluated in order to monitor the overall efficiency. Patients were given 150mg-200mg of AG-221 either once or twice daily in 28 day cycles. 15 patients (33%) went into complete remission, 10 patients (22%) went into partial remission. In addition to this 17 (38%) of patients disease became stable. Other cases have included complete remission, lasting up to eight months some are still ongoing. It is safe to say that this drug has the potential to be revolutionary.